Which Big Name Protease Inhibitor Left the Hepatitis C Market?
Boehringer pulls faldepravir and exits hepatitis C market
Unable to challenge all-oral options from Gilead and others
Germany’s Boehringer Ingelheim is bowing out of the race to develop oral hepatitis C virus (HCV) therapies and has discontinued development of lead candidate faldepravir.
After a strategic review of its business, the company said it had elected to withdraw all regulatory filings for faldepravir – a protease inhibitor – because the “HCV treatment environment has significantly and rapidly evolved” in the last couple of years.
Continue reading this entire article: